{ "meta": { "disclaimer": "Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.", "terms": "https://open.fda.gov/terms/", "license": "https://open.fda.gov/license/", "last_updated": "2026-07-30", "results": { "skip": 0, "limit": 1, "total": 1 } }, "results": [ { "safetyreportversion": "1", "safetyreportid": "19685217", "primarysourcecountry": "US", "occurcountry": "US", "transmissiondateformat": "102", "transmissiondate": "20211014", "reporttype": "1", "serious": "1", "seriousnessother": "1", "receivedateformat": "102", "receivedate": "20210811", "receiptdateformat": "102", "receiptdate": "20210811", "fulfillexpeditecriteria": "1", "companynumb": "US-ASTRAZENECA-2021A664965", "duplicate": "1", "reportduplicate": { "duplicatesource": "ASTRAZENECA", "duplicatenumb": "US-ASTRAZENECA-2021A664965" }, "primarysource": { "reportercountry": "US", "qualification": "3" }, "sender": { "sendertype": "2", "senderorganization": "FDA-Public Use" }, "receiver": { "receivertype": "6", "receiverorganization": "FDA" }, "patient": { "patientonsetage": "78", "patientonsetageunit": "801", "patientweight": "68.7", "patientsex": "2", "reaction": [ { "reactionmeddraversionpt": "24.0", "reactionmeddrapt": "Metastases to meninges", "reactionoutcome": "6" }, { "reactionmeddraversionpt": "24.0", "reactionmeddrapt": "Nausea", "reactionoutcome": "6" }, { "reactionmeddraversionpt": "24.0", "reactionmeddrapt": "Diarrhoea", "reactionoutcome": "6" }, { "reactionmeddraversionpt": "24.0", "reactionmeddrapt": "Intentional product misuse", "reactionoutcome": "6" }, { "reactionmeddraversionpt": "24.0", "reactionmeddrapt": "Feeling abnormal", "reactionoutcome": "6" }, { "reactionmeddraversionpt": "24.0", "reactionmeddrapt": "Dehydration", "reactionoutcome": "6" } ], "drug": [ { "drugcharacterization": "1", "medicinalproduct": "TAGRISSO", "drugbatchnumb": "UNKNOWN", "drugauthorizationnumb": "208065", "drugstructuredosagenumb": "160", "drugstructuredosageunit": "003", "drugdosagetext": "160.0MG UNKNOWN", "drugdosageform": "TABLET", "drugadministrationroute": "048", "drugindication": "LUNG NEOPLASM MALIGNANT", "actiondrug": "3", "activesubstance": { "activesubstancename": "OSIMERTINIB" }, "openfda": { "application_number": [ "NDA208065" ], "brand_name": [ "TAGRISSO" ], "generic_name": [ "OSIMERTINIB" ], "manufacturer_name": [ "AstraZeneca Pharmaceuticals LP" ], "product_ndc": [ "0310-1248", "0310-1349", "0310-1350", "0310-1251" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "OSIMERTINIB" ], "rxcui": [ "1721565", "1721571", "1721581", "1721583" ], "spl_id": [ "d703b5ed-4b1c-44fe-8005-ebe3d8f563e6" ], "spl_set_id": [ "5e81b4a7-b971-45e1-9c31-29cea8c87ce7" ], "package_ndc": [ "0310-1349-30", "0310-1350-30", "0310-1350-95", "0310-1350-99", "0310-1248-30", "0310-1251-30" ], "nui": [ "N0000175605", "N0000175082", "N0000190114", "N0000185506", "N0000191266", "N0000190113" ], "pharm_class_epc": [ "Kinase Inhibitor [EPC]" ], "pharm_class_moa": [ "Kinase Inhibitors [MoA]", "Cytochrome P450 3A Inhibitors [MoA]", "Cytochrome P450 3A4 Inducers [MoA]", "Cytochrome P450 1A2 Inducers [MoA]", "Breast Cancer Resistance Protein Inhibitors [MoA]" ], "unii": [ "3C06JJ0Z2O" ] } }, { "drugcharacterization": "2", "medicinalproduct": "LEXAPRO", "activesubstance": { "activesubstancename": "ESCITALOPRAM OXALATE" }, "openfda": { "application_number": [ "NDA021323" ], "brand_name": [ "LEXAPRO" ], "generic_name": [ "ESCITALOPRAM" ], "manufacturer_name": [ "Allergan, Inc." ], "product_ndc": [ "0456-2005", "0456-2010", "0456-2020", "0456-2101" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "ESCITALOPRAM OXALATE" ], "rxcui": [ "349332", "351249", "351250", "351285", "352272", "352273", "404408", "404420" ], "spl_id": [ "9ff46a66-0f97-4a78-9d18-ec576f63bae7" ], "spl_set_id": [ "13bb8267-1cab-43e5-acae-55a4d957630a" ], "package_ndc": [ "0456-2005-01", "0456-2010-01", "0456-2010-11", "0456-2010-63", "0456-2020-01", "0456-2020-11", "0456-2020-63", "0456-2101-08" ], "unii": [ "5U85DBW7LO" ] } }, { "drugcharacterization": "2", "medicinalproduct": "WELLBUTRIN", "activesubstance": { "activesubstancename": "BUPROPION HYDROCHLORIDE" }, "openfda": { "application_number": [ "NDA021515", "NDA020358" ], "brand_name": [ "WELLBUTRIN XL", "WELLBUTRIN SR" ], "generic_name": [ "BUPROPION HYDROCHLORIDE" ], "manufacturer_name": [ "Bausch Health US LLC", "GlaxoSmithKline LLC" ], "product_ndc": [ "0187-0730", "0187-0731", "0173-0135", "0173-0947", "0173-0722" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "BUPROPION HYDROCHLORIDE" ], "rxcui": [ "993541", "993545", "993557", "993564", "993503", "993511", "993518", "993528", "993536", "993537" ], "spl_id": [ "22308f71-fc56-430d-b559-bed47e17a46c", "5ffc8b63-7d69-4f3a-bf05-a9c138724a91" ], "spl_set_id": [ "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "cbc8c074-f080-4489-a5ae-207b5fadeba3" ], "package_ndc": [ "0187-0730-30", "0187-0730-90", "0187-0730-07", "0187-0731-30", "0187-0731-07", "0173-0947-55", "0173-0135-55", "0173-0722-00" ], "unii": [ "ZG7E5POY8O" ] } }, { "drugcharacterization": "2", "medicinalproduct": "LEVOTHYROXINE.", "activesubstance": { "activesubstancename": "LEVOTHYROXINE" } }, { "drugcharacterization": "1", "medicinalproduct": "TAGRISSO", "drugbatchnumb": "UNKNOWN", "drugauthorizationnumb": "208065", "drugstructuredosagenumb": "80", "drugstructuredosageunit": "003", "drugdosagetext": "80.0MG UNKNOWN", "drugdosageform": "TABLET", "drugadministrationroute": "048", "drugindication": "LUNG NEOPLASM MALIGNANT", "actiondrug": "3", "activesubstance": { "activesubstancename": "OSIMERTINIB" }, "openfda": { "application_number": [ "NDA208065" ], "brand_name": [ "TAGRISSO" ], "generic_name": [ "OSIMERTINIB" ], "manufacturer_name": [ "AstraZeneca Pharmaceuticals LP" ], "product_ndc": [ "0310-1248", "0310-1349", "0310-1350", "0310-1251" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "OSIMERTINIB" ], "rxcui": [ "1721565", "1721571", "1721581", "1721583" ], "spl_id": [ "d703b5ed-4b1c-44fe-8005-ebe3d8f563e6" ], "spl_set_id": [ "5e81b4a7-b971-45e1-9c31-29cea8c87ce7" ], "package_ndc": [ "0310-1349-30", "0310-1350-30", "0310-1350-95", "0310-1350-99", "0310-1248-30", "0310-1251-30" ], "nui": [ "N0000175605", "N0000175082", "N0000190114", "N0000185506", "N0000191266", "N0000190113" ], "pharm_class_epc": [ "Kinase Inhibitor [EPC]" ], "pharm_class_moa": [ "Kinase Inhibitors [MoA]", "Cytochrome P450 3A Inhibitors [MoA]", "Cytochrome P450 3A4 Inducers [MoA]", "Cytochrome P450 1A2 Inducers [MoA]", "Breast Cancer Resistance Protein Inhibitors [MoA]" ], "unii": [ "3C06JJ0Z2O" ] } }, { "drugcharacterization": "1", "medicinalproduct": "TAGRISSO", "drugbatchnumb": "UNKNOWN", "drugauthorizationnumb": "208065", "drugstructuredosagenumb": "120", "drugstructuredosageunit": "003", "drugdosagetext": "120.0MG UNKNOWN", "drugdosageform": "TABLET", "drugadministrationroute": "048", "drugindication": "LUNG NEOPLASM MALIGNANT", "actiondrug": "3", "activesubstance": { "activesubstancename": "OSIMERTINIB" }, "openfda": { "application_number": [ "NDA208065" ], "brand_name": [ "TAGRISSO" ], "generic_name": [ "OSIMERTINIB" ], "manufacturer_name": [ "AstraZeneca Pharmaceuticals LP" ], "product_ndc": [ "0310-1248", "0310-1349", "0310-1350", "0310-1251" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "OSIMERTINIB" ], "rxcui": [ "1721565", "1721571", "1721581", "1721583" ], "spl_id": [ "d703b5ed-4b1c-44fe-8005-ebe3d8f563e6" ], "spl_set_id": [ "5e81b4a7-b971-45e1-9c31-29cea8c87ce7" ], "package_ndc": [ "0310-1349-30", "0310-1350-30", "0310-1350-95", "0310-1350-99", "0310-1248-30", "0310-1251-30" ], "nui": [ "N0000175605", "N0000175082", "N0000190114", "N0000185506", "N0000191266", "N0000190113" ], "pharm_class_epc": [ "Kinase Inhibitor [EPC]" ], "pharm_class_moa": [ "Kinase Inhibitors [MoA]", "Cytochrome P450 3A Inhibitors [MoA]", "Cytochrome P450 3A4 Inducers [MoA]", "Cytochrome P450 1A2 Inducers [MoA]", "Breast Cancer Resistance Protein Inhibitors [MoA]" ], "unii": [ "3C06JJ0Z2O" ] } }, { "drugcharacterization": "2", "medicinalproduct": "MARINOL", "activesubstance": { "activesubstancename": "DRONABINOL" }, "openfda": { "application_number": [ "NDA018651" ], "brand_name": [ "MARINOL" ], "generic_name": [ "DRONABINOL" ], "manufacturer_name": [ "ThePharmaNetwork, LLC" ], "product_ndc": [ "53097-568", "53097-569", "53097-570", "53097-571", "53097-572", "53097-573" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "DRONABINOL" ], "rxcui": [ "197634", "197635", "197636", "205641", "205642", "205645" ], "spl_id": [ "628f9609-6583-49be-be77-b64cfbc46fd7", "5ce802d5-e8ab-4cd1-9ba0-1f39f22ddd48" ], "spl_set_id": [ "628f9609-6583-49be-be77-b64cfbc46fd7", "d0efeeec-640d-43c3-8f0a-d31324a11c68" ], "package_ndc": [ "53097-568-60", "53097-569-60", "53097-570-60", "53097-571-60", "53097-572-60", "53097-573-60" ], "nui": [ "N0000175782", "M0003267" ], "pharm_class_epc": [ "Cannabinoid [EPC]" ], "pharm_class_cs": [ "Cannabinoids [CS]" ], "unii": [ "7J8897W37S" ] } } ] } } ] }